급성 전순환계 대혈관 폐색 뇌졸중 환자에서 인터루킨-6 수용체 억제제와 혈관내 치료를 병용한 치료의 효능 및 안전성 -2 (IRIS-2)
급성 전순환계 대혈관 폐색 뇌졸중 환자에서 인터루킨-6 수용체 억제제와 혈관 내 치료의 병용 요법에 대한 효능 및 안전성: 무작위 배정, 이중 맹검, 위약 대조 임상 시험-2 (IRIS-2)
This study is a randomized, double-blind, placebo-controlled clinical trial. Investigators aim to assess the efficacy and safety of interleukin-6 receptor inhibitor combined with endovascular treatment in patients with acute anterior circulation large vessel occlusion stroke.
연구 개요
상세 설명
The study population are patients with acute anterior circulation large vessel occlusion stroke and planned to undergo endovascular treatment. All participants are randomly assigned in a 1:1 ratio to the tocilizumab group or the placebo group. In tocilizumab group, participants will receive tocilizumab combined endovascular treatment. And in placebo group, participants will receive placebo combined endovascular treatment. All participants will be visited immediately postoperatively, at 24 hours, 7 days, and 90 days after randomization.
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Beijing, 중국, 100053
- Xuanwu Hospital, Capital Medical University
-
Beijing, 중국
- Beijing Red Cross Emergency Medical Center
-
Shenzhen, 중국
- Shenzhen Longhua District People's Hospital
-
-
Anhui
-
Suzhou, Anhui, 중국
- Suzhou Hospital of Anhui Medical University
-
Suzhou, Anhui, 중국
- Si Country People's Hospital
-
Suzhou, Anhui, 중국
- Suixi County Hospital
-
-
Fujian
-
Zhangzhou, Fujian, 중국
- Zhangzhou Municipal Hospital
-
-
Guangxi
-
Qinzhou, Guangxi, 중국
- Lingshan County People's Hospital
-
-
Hebei
-
Langfang, Hebei, 중국
- JingDong ZhongMei Hospital
-
Qinhuangdao, Hebei, 중국
- The second Hospital of Qinhuangdao
-
Tangshan, Hebei, 중국
- Tangshan Workers Hospital
-
Tangshan, Hebei, 중국
- Yutian Hospital
-
-
Heilongjiang
-
Harbin, Heilongjiang, 중국
- The First Affiliated Hospital of Harbin Medical University
-
-
Henan
-
Anyang, Henan, 중국
- The People's Hospital of Anyang
-
Hebi, Henan, 중국
- Jun County People's Hospital
-
Jiaozuo, Henan, 중국
- Jiaozuo No.2 People's Hospital
-
Luoyang, Henan, 중국
- Luoyang Central Hospital
-
Luoyang, Henan, 중국
- Mengjin County People's Hospital
-
Nanyang, Henan, 중국
- Nanyang Central Hospital
-
Nanyang, Henan, 중국
- Nanyang Nanshi Hospital
-
Nanyang, Henan, 중국
- Tanghe County People's Hospital
-
Nanyang, Henan, 중국
- Nanyang Second People's Hospital
-
Puyang, Henan, 중국
- Puyang Oilfield General Hospital
-
Shangqiu, Henan, 중국
- Shangqiu No.1 People's Hospital
-
Shangqiu, Henan, 중국
- Ningling County People's Hospital
-
Xinxiang, Henan, 중국
- Xinxiang Central Hospital
-
Xinxiang, Henan, 중국
- Huixian People's Hospital
-
Xinxiang, Henan, 중국
- The First Affiliated Hospital of Henan Medical University
-
Zhengzhou, Henan, 중국
- Henan Provincial People's Hospital
-
Zhoukou, Henan, 중국
- Xihua County People's Hospital
-
-
Hubei
-
Wuhan, Hubei, 중국
- Tianyou Hospital Affliated to Wuhan University of Science &Technology
-
Xiangyang, Hubei, 중국
- Xiangyang No.1 People's hospital
-
-
Inner Mongolia
-
Xing’an, Inner Mongolia, 중국
- Xing'an league People's Hospital
-
-
Jiangsu
-
Nantong, Jiangsu, 중국
- Nantong First People's Hospital
-
-
Shandong
-
Binzhou, Shandong, 중국
- Binzhou Medical University Hospital
-
Dongying, Shandong, 중국
- People's Hospital of Dongying
-
Linyi, Shandong, 중국
- Linyi People's Hospital
-
Linyi, Shandong, 중국
- Linshu Country People's Hospital
-
Qingdao, Shandong, 중국
- Qingdao Huangdao District Hospital of Traditional Chinese Medicine
-
Zibo, Shandong, 중국
- Zibo Central Hospital
-
Zibo, Shandong, 중국
- Yiyuan Country People's Hospital
-
-
Shanxi
-
Jincheng, Shanxi, 중국
- Jincheng People's Hospital
-
Taiyuan, Shanxi, 중국
- Shanxi Bethune Hospital
-
Taiyuan, Shanxi, 중국
- Shanxi Medical University First Hospital
-
Xianyang, Shanxi, 중국
- The People's Hospital of Xianyang
-
Yulin, Shanxi, 중국
- Daliuta Experimental District People's Hospital of Shenmu City
-
-
Wuhan
-
Zhongxiang, Wuhan, 중국
- Zhongxiang Traditional Chinese Medical Hospital
-
-
Zhejiang
-
Jiaxing, Zhejiang, 중국
- Jiaxing First Hospital
-
Lishui, Zhejiang, 중국
- Lishui Central Hospital
-
Ningbo, Zhejiang, 중국
- Ningbo Medical Center Lihuili Hospital
-
Ningbo, Zhejiang, 중국
- Ningbo NO.2 Hospital
-
Taizhou, Zhejiang, 중국
- Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University
-
Wenzhou, Zhejiang, 중국
- Wenzhou People's Hospital
-
Yueqing, Zhejiang, 중국
- Yueqing People's Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age 18 years or greater, male or female;
- Acute ischemic stroke caused by occlusion of intracranial segment of the internal carotid artery, middle cerebral artery M1 or proximal/dominant M2 segment;
- Decided to undergo emergency endovascular treatment;
- Time from stroke onset to arterial puncture within 24 hours;
- National Institutes of Health Stroke Scale (NIHSS) score ≥ 6;
- Signed informed consent from the patients or the legally authorized representatives.
Exclusion Criteria:
- Intracerebral hemorrhage, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage;
- Pre-stroke modified Rankin scale (mRS) score >1;
- Known allergy to tocilizumab or excipients;
- Known allergy to iodinated contrast agents;
- Anticipated difficulty in completing endovascular treatment due to vascular tortuosity;
- History of congenital or acquired bleeding disorders, coagulation factor deficiency diseases, or thrombocytopenic diseases;
- Systolic blood pressure ≥180mmHg or diastolic blood pressure ≥110mmHg despite blood pressure control;
- Neutrophils <2×109 /L;
- Platelets <100×109 /L;
- Blood glucose <2.8mmol/L (50 mg/dL) or >22.2mmol/L (400 mg/dL);
- Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels >2 times the upper limit of normal;
- Known recent or current serum creatinine >2 times the upper limit of normal or estimated glomerular filtration rate (eGFR) <60 mL/min;
- Pregnant, lactating, or planning pregnancy within 90 days;
- Severe mental disorders or inability to comply with informed consent and follow-up requirements due to dementia;
- Concurrent malignant tumors or severe systemic diseases with expected survival of less than 90 days;
- Presence of autoimmune diseases or use of immunosuppressive drugs;
- Systemic infectious diseases;
- Participation in another interventional clinical study within 30 days before randomization or currently participating in another interventional clinical study;
- Considered by the investigator to have other conditions that might affect compliance or preclude participation in this study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Tocilizumab group
Endovascular treatment combined 240 mg tocilizumab injection once. |
240 mg of tocilizumab injection will be diluted in 0.9% NaCl solution to prepare a total solution volume of 100 mL. The solution will be administered via intravenous infusion immediately after randomization, and no later than 30 minutes, with an infusion duration of more than 1 hour. |
|
위약 비교기: Placebo group
Endovascular treatment combined equivalent volume of placebo once. |
An equivalent volume of placebo will be diluted in 0.9% NaCl solution to prepare a total solution volume of 100 mL. The solution will be administered via intravenous infusion immediately after randomization, and no later than 30 minutes, with an infusion duration of more than 1 hour. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
modified Rankin Scale (mRS) score at 90 days
기간: 90 days
|
The mRS ranges from 0 to 6, with higher scores indicating worse outcomes. |
90 days
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
24시간 경과 시 경색 부피
기간: 24시간
|
24시간
|
|
|
24시간 이내 증상성 뇌내출혈 발생률
기간: 24시간
|
24시간
|
|
|
24시간 이내 발생한 모든 뇌내출혈의 발생률
기간: 24시간
|
24시간
|
|
|
7일 또는 조기 퇴원 시 폐렴 환자의 비율
기간: 7일 또는 조기 퇴원 시
|
7일 또는 조기 퇴원 시
|
|
|
Proportion of patients with mRS score 0-2 at 90 days
기간: 90 days and 1year
|
90 days and 1year
|
|
|
Proportion of patients with mRS score 0-1 at 90 days
기간: 90 days and 1year
|
90 days and 1year
|
|
|
Proportion of Barthel Index (BI) 95-100 at 90 days
기간: 90 days and 1year
|
90 days and 1year
|
|
|
Mortality at 90 days
기간: 90 days and 1year
|
90 days and 1year
|
|
|
National Institutes of Health Stroke Scale (NIHSS) score at 7 days or at early discharge
기간: 7 days or at early discharge
|
The NIHSS ranges from 0 to 42, with higher scores indicating worse outcomes. |
7 days or at early discharge
|
|
EuroQol Five-Dimension Five-Level Questionnaire (EQ-5D-5L) at 90 days
기간: 90 days and 1year
|
The EQ-5D-5L includes 5 dimensions: mobility, self-care, usual activities,pain/discomfort, and anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, and 5= extreme problems. Higher scoresindicating worse quality of life. |
90 days and 1year
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
modified Rankin Scale (mRS) score
기간: 1 year
|
The mRS ranges from 0 to 6, with higher scores indicating worse outcomes. |
1 year
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
- IRIS-2
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Related data will be shared if full study protocol and statistical analysis plan are provided with reasonable design.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .